126 related articles for article (PubMed ID: 38316193)
1. Cost-effectiveness of weekly adaptive radiotherapy versus standard IMRT in head and neck cancer alongside the ARTIX trial.
Perrier L; Balusson F; Morelle M; Castelli J; Thariat J; Benezery K; Hasbini A; Gery B; Berger A; Liem X; Guihard S; Chapet S; Thureau S; Auberdiac P; Pommier P; Ruffier A; Devillers A; Oger E; Campillo-Gimenez B; de Crevoisier R
Radiother Oncol; 2024 Apr; 193():110116. PubMed ID: 38316193
[TBL] [Abstract][Full Text] [Related]
2. Weekly Adaptive Radiotherapy vs Standard Intensity-Modulated Radiotherapy for Improving Salivary Function in Patients With Head and Neck Cancer: A Phase 3 Randomized Clinical Trial.
Castelli J; Thariat J; Benezery K; Hasbini A; Gery B; Berger A; Liem X; Guihard S; Chapet S; Thureau S; Auberdiac P; Pommier P; Ruffier A; Perrier L; Devillers A; Campillo-Gimenez B; de Crevoisier R
JAMA Oncol; 2023 Aug; 9(8):1056-1064. PubMed ID: 37261806
[TBL] [Abstract][Full Text] [Related]
3. Impact of head and neck cancer adaptive radiotherapy to spare the parotid glands and decrease the risk of xerostomia.
Castelli J; Simon A; Louvel G; Henry O; Chajon E; Nassef M; Haigron P; Cazoulat G; Ospina JD; Jegoux F; Benezery K; de Crevoisier R
Radiat Oncol; 2015 Jan; 10():6. PubMed ID: 25573091
[TBL] [Abstract][Full Text] [Related]
4. Reducing Salivary Toxicity with Adaptive Radiotherapy (ReSTART): A Randomized Controlled Trial Comparing Conventional IMRT to Adaptive IMRT in Head and Neck Squamous Cell Carcinomas.
Ghosh Laskar S; Sinha S; Kumar A; Samanta A; Mohanty S; Kale S; Khan F; Lewis Salins S; Murthy V
Clin Oncol (R Coll Radiol); 2024 Jun; 36(6):353-361. PubMed ID: 38575432
[TBL] [Abstract][Full Text] [Related]
5. Recovery of Salivary Function: Contralateral Parotid-sparing Intensity-modulated Radiotherapy versus Bilateral Superficial Lobe Parotid-sparing Intensity-modulated Radiotherapy.
Miah AB; Gulliford SL; Morden J; Newbold KL; Bhide SA; Zaidi SH; Hall E; Harrington KJ; Nutting CM
Clin Oncol (R Coll Radiol); 2016 Sep; 28(9):e69-e76. PubMed ID: 26994893
[TBL] [Abstract][Full Text] [Related]
6. Comparison of xerostomia incidence after three-dimensional conformal radiation therapy and contralateral superficial lobe parotid-sparing intensity-modulated radiotherapy for oropharyngeal and hypopharyngeal cancer.
Kawamoto T; Nihei K; Nakajima Y; Kito S; Sasai K; Karasawa K
Auris Nasus Larynx; 2018 Oct; 45(5):1073-1079. PubMed ID: 29397249
[TBL] [Abstract][Full Text] [Related]
7. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial.
Nutting CM; Morden JP; Harrington KJ; Urbano TG; Bhide SA; Clark C; Miles EA; Miah AB; Newbold K; Tanay M; Adab F; Jefferies SJ; Scrase C; Yap BK; A'Hern RP; Sydenham MA; Emson M; Hall E;
Lancet Oncol; 2011 Feb; 12(2):127-36. PubMed ID: 21236730
[TBL] [Abstract][Full Text] [Related]
8. Can dose reduction to one parotid gland prevent xerostomia?--A feasibility study for locally advanced head and neck cancer patients treated with intensity-modulated radiotherapy.
Anand AK; Jain J; Negi PS; Chaudhoory AR; Sinha SN; Choudhury PS; Kumar R; Munjal RK
Clin Oncol (R Coll Radiol); 2006 Aug; 18(6):497-504. PubMed ID: 16909975
[TBL] [Abstract][Full Text] [Related]
9. Protons in head-and-neck cancer: bridging the gap of evidence.
Ramaekers BL; Grutters JP; Pijls-Johannesma M; Lambin P; Joore MA; Langendijk JA
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1282-8. PubMed ID: 23273998
[TBL] [Abstract][Full Text] [Related]
10. Impact of salivary gland dosimetry on post-IMRT recovery of saliva output and xerostomia grade for head-and-neck cancer patients treated with or without contralateral submandibular gland sparing: a longitudinal study.
Wang ZH; Yan C; Zhang ZY; Zhang CP; Hu HS; Tu WY; Kirwan J; Mendenhall WM
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1479-87. PubMed ID: 20934262
[TBL] [Abstract][Full Text] [Related]
11. Two-year and lifetime cost-effectiveness of intensity modulated radiation therapy versus 3-dimensional conformal radiation therapy for head-and-neck cancer.
Kohler RE; Sheets NC; Wheeler SB; Nutting C; Hall E; Chera BS
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):683-9. PubMed ID: 24138916
[TBL] [Abstract][Full Text] [Related]
12. Parotid gland sparing IMRT for head and neck cancer improves xerostomia related quality of life.
van Rij CM; Oughlane-Heemsbergen WD; Ackerstaff AH; Lamers EA; Balm AJ; Rasch CR
Radiat Oncol; 2008 Dec; 3():41. PubMed ID: 19068126
[TBL] [Abstract][Full Text] [Related]
13. The effect of parotid gland-sparing intensity-modulated radiotherapy on salivary composition, flow rate and xerostomia measures.
Richards TM; Hurley T; Grove L; Harrington KJ; Carpenter GH; Proctor GB; Nutting CM
Oral Dis; 2017 Oct; 23(7):990-1000. PubMed ID: 28434191
[TBL] [Abstract][Full Text] [Related]
14. Intensity-modulated radiotherapy reduces radiation-induced morbidity and improves health-related quality of life: results of a nonrandomized prospective study using a standardized follow-up program.
Vergeer MR; Doornaert PA; Rietveld DH; Leemans CR; Slotman BJ; Langendijk JA
Int J Radiat Oncol Biol Phys; 2009 May; 74(1):1-8. PubMed ID: 19111400
[TBL] [Abstract][Full Text] [Related]
15. Clinical and dosimetric impact of adaptive intensity-modulated radiotherapy in locally advanced head-and-neck cancer.
Maheshwari G; Dhanawat A; Kumar HS; Sharma N; Jakhar SL
J Cancer Res Ther; 2020; 16(3):600-604. PubMed ID: 32719274
[TBL] [Abstract][Full Text] [Related]
16. Intensity-modulated radiotherapy vs. parotid-sparing 3D conformal radiotherapy. Effect on outcome and toxicity in locally advanced head and neck cancer.
Lambrecht M; Nevens D; Nuyts S
Strahlenther Onkol; 2013 Mar; 189(3):223-9. PubMed ID: 23319256
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of salivary gland function after treatment of head-and-neck tumors with intensity-modulated radiotherapy by quantitative pertechnetate scintigraphy.
Münter MW; Karger CP; Hoffner SG; Hof H; Thilmann C; Rudat V; Nill S; Wannenmacher M; Debus J
Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):175-84. PubMed ID: 14697436
[TBL] [Abstract][Full Text] [Related]
18. Intensity-modulated radiation therapy (IMRT) versus 3-dimensional conformal radiation therapy (3D-CRT) for head and neck cancer: cost-effectiveness analysis.
Marta GN; Weltman E; Ferrigno R
Rev Assoc Med Bras (1992); 2018 Apr; 64(4):318-323. PubMed ID: 30133610
[TBL] [Abstract][Full Text] [Related]
19. Concurrent cisplatin and dose escalation with intensity-modulated radiotherapy (IMRT) versus conventional radiotherapy for locally advanced head and neck squamous cell carcinomas (HNSCC): GORTEC 2004-01 randomized phase III trial.
Tao Y; Auperin A; Blanchard P; Alfonsi M; Sun XS; Rives M; Pointreau Y; Castelli J; Graff P; Wong Hee Kam S; Thariat J; Veresezan O; Heymann S; Renard-Oldrini S; Lafond C; Cornely A; Casiraghi O; Boisselier P; Lapeyre M; Biau J; Bourhis J
Radiother Oncol; 2020 Sep; 150():18-25. PubMed ID: 32417348
[TBL] [Abstract][Full Text] [Related]
20. Quality of life after parotid-sparing IMRT for head-and-neck cancer: a prospective longitudinal study.
Lin A; Kim HM; Terrell JE; Dawson LA; Ship JA; Eisbruch A
Int J Radiat Oncol Biol Phys; 2003 Sep; 57(1):61-70. PubMed ID: 12909216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
